AstraZeneca wins rapid regulatory approval for new uses of two of its important cancer drugs in Japan

AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets.

The decisions by the Japanese Ministry of Health, Labour and Welfare reflect an increased urgency by officials in the country to access modern medicines, after many years of slow adoption, reports Reuters.

AstraZeneca said on Monday that its Imfinzi immunotherapy drug had been approved for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.


Imfinzi was only given a U.S. green light for treating such stage III lung cancer in February and it is still awaiting approval in the European Union. Japan also approved Lynparza, which AstraZeneca markets with Merck & Co, for breast cancer.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

AI helps organizations grow profits 80 percent faster
Students develop strong leadership skills through DPS Model United Nation
Paperfly launches delivery services covering 64 districts in Bangladesh
Primary students of ISD raise fund for endangered animals
Arial Beel: A hub of natural beauty and resources in Bangladesh
Grameenphone brings in the iPhone 11 series in Bangladesh


News of the Month

Scroll Up
%d bloggers like this: